|
||||||||
|
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
Select publications
Albain KS et al. Global phase III study of gemcitabine plus paclitaxel (GT) vs paclitaxel (T) as frontline therapy for metastatic breast cancer (MBC): First report of overall survival. Proc ASCO 2004;Abstract 510.
Ferrara N, Davis-Smyth T. The biology of vascular endothelial growth factor. Endocr Rev 1997;18(1):4-25. No abstract available
Ferrara N et al. Molecular and biological properties of the vascular endothelial growth factor family of proteins. Endocr Rev 1992;13(1):18-32. No abstract available
Goldstein L et al. E2197: Phase III AT (doxorubicin/docetaxel) vs AC (doxorubicin/
cyclophosphamide) in the adjuvant treatment of node positive and high risk node
negative breast cancer. Proc ASCO 2005; Abstract 512.
Gradishar WJ et al. Neoadjuvant docetaxel followed by adjuvant doxorubicin and cyclophosphamide in patients with stage III breast cancer. Ann Oncol 2005;16(8):1297-304. Abstract
Jones SE et al. Final analysis: TC (docetaxel/cyclophosphamide, 4 cycles) has a superior disease-free survival compared to standard AC (doxorubicin/cyclophosphamide) in 1016 women with early stage breast cancer. Presentation. San Antonio Breast Cancer Symposium 2005;Abstract 40.
Kim C et al. A comparison of estrogen receptor (ER) measurement by three methods in node negative, estrogen receptor (ER) positive breast cancer: Ligand binding (LB), immunohistochemistry (IHC), and quantitative RT-PC. San Antonio Breast Cancer Symposium 2006;Abstract 3116.
Le Deley MC et al. Anthracyclines, mitoxantrone, radiotherapy, and granulocyte colony-stimulating factor: Risk factors for leukemia and myelodysplastic syndrome after breast cancer. J Clin Oncol 2007;25(3):292-300. Abstract
Mohsin SK et al. Neoadjuvant trastuzumab induces apoptosis in primary breast cancers.
J Clin Oncol 2005;23(11):2460-8. Abstract
Paik S et al. Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer. J Clin Oncol 2006;24(23):3726-34. Abstract
Slamon D et al. BCIRG 006: 2nd interim analysis phase III randomized trial comparing doxorubicin and cyclophosphamide followed by docetaxel (AC 
T) with doxorubicin and cyclophosphamide followed by docetaxel and trastuzumab (AC TH) with docetaxel, carboplatin and trastuzumab (TCH) in Her2neu positive early breast cancer patients. San Antonio Breast Cancer Symposium 2006;Abstract 52.
Swain SM. A step in the right direction. J Clin Oncol 2006;24(23):3717-8. No abstract available
Wedam SB et al. Antiangiogenic and antitumor effects of bevacizumab in patients with inflammatory and locally advanced breast cancer. J Clin Oncol 2006;24(5):769-77. Abstract
 |
 |
